MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
DNLI — Denali Therapeutics Inc. Common Stock
NasdaqDenali Therapeutics Inc. Common Stock
$20.00
-0.53(-2.58%)
- O
- 20.85
- H
- 20.85
- L
- 19.93
- V
- 1.63M
⏱️ End-of-day dataAs of Oct 2, 2026
Chart
About DNLI
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SectorNot available
IPO DateDec 8, 2017
Employees507
Stock ExchangeNasdaq
Ticker SymbolDNLI
Key Financial Statistics
| Market Cap | $3.20B |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $13.75 - $27.30 |
| 52-Week Avg Volume | 1.68M |
| VWAP | $20.08 |
| Transactions | 20,770 |
| Total Recorded Bars | 2,215 days |